Bovie Medical Corporation, a medical device company, develops, manufactures, and markets electrosurgical devices and technologies, and related medical products used in doctor's offices, surgery centers, and hospitals worldwide. The company provides electrosurgical products, including desiccators, generators, electrodes, electrosurgical pencils, and various ancillary disposable products used during surgical procedures in gynecology, urology, plastic surgery, dermatology, veterinary, and other surgical markets for the cutting and coagulation of tissue. It also offers electrosurgical disposables comprising Resistick II, a proprietary coating applied to stainless steel that resist eschar during surgery; and disposable laparoscopic electrodes for use by physicians in the areas of gynecology, general surgery, and urology. In addition, the company provides battery operated cauteries for precise hemostasis in ophthalmology; nerve locator stimulator primarily used for identifying motor nerves in hand and facial reconstructive surgery; penlights for use in offices; and specialty lighting instruments for use in ophthalmology, as well as distributes specialty lighting instruments for general surgery, hip replacement surgery, and endotracheal tubes placement. Further, it develops J-Plasma, a patented helium-based plasma surgical product, as well as designs, develops, and manufactures electrosurgical equipment by producing equipment for medical device manufacturers through original equipment manufacturing agreements. Bovie Medical Corporation markets its products to distributors under own brands, such as Bovie, IDS, and DERM, as well as under a private label. The company was formerly known as An-Con Genetics Inc. and changed its name to Bovie Medical Corporation in October 1998. Bovie Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:BVX
Previous SymbolAMEX:BVX
CUSIPN/A
Phone+1-727-3842323
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees211
Outstanding Shares33,200,000
Market Cap$0.00
OptionableOptionable
Bovie Medical (NYSEAMERICAN:BVX) Frequently Asked Questions
What is Bovie Medical's stock symbol?
Bovie Medical trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BVX."
How were Bovie Medical's earnings last quarter?
Bovie Medical Co. (NYSEAMERICAN:BVX) issued its quarterly earnings data on Thursday, November, 1st. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.08. The medical device company earned $3.67 million during the quarter, compared to the consensus estimate of $3.67 million. The firm's quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.09) EPS. View Bovie Medical's Earnings History.
When is Bovie Medical's next earnings date?
What guidance has Bovie Medical issued on next quarter's earnings?
Bovie Medical issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $(0.25-0.26) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.34). The company issued revenue guidance of $15.8-16.2 million, compared to the consensus revenue estimate of $15.35 million.
What price target have analysts set for BVX?
2 equities research analysts have issued 1-year price objectives for Bovie Medical's stock. Their forecasts range from $8.50 to $11.00. On average, they anticipate Bovie Medical's stock price to reach $9.75 in the next twelve months. This suggests a possible upside of 63.3% from the stock's current price. View Analyst Price Targets for Bovie Medical.
What is the consensus analysts' recommendation for Bovie Medical?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bovie Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bovie Medical.
Has Bovie Medical been receiving favorable news coverage?
Press coverage about BVX stock has trended somewhat positive on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bovie Medical earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave headlines about the medical device company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Bovie Medical's key competitors?
Some companies that are related to Bovie Medical include Advanced Medical Solutions (AMS), Akers Biosciences (AKR), Ansell (ANN), Clover (CLV), CONVATEC Grp PL/ADR (CNVVY), CRH Medical (CRHM), CRH Medical (CRH), Daxor (DXR), Enerplus (ERF), Essilor International Cmgn Gnl D Optq (EI), Gerresheimer (GXI), InfuSystem (INFU), Iris BioTechnologies (IRSB), IsoRay (ISR) and IsoRay (ISR).
Who are Bovie Medical's key executives?
Bovie Medical's management team includes the folowing people:
- Mr. Charles D. Goodwin II, CEO & Director (Age 52)
- Mr. Jay D. Ewers, CFO, Treasurer & Sec. (Age 57)
- Mr. Moshe Citronowicz, Sr. VP (Age 65)
- Mr. Todd Hornsby, VP & GM of Advanced Energy
- Mr. Jeffrey Rencher, VP of Sales & Marketing - Surgical Products (Age 51)
Who are Bovie Medical's major shareholders?
Bovie Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.66%), Perkins Capital Management Inc. (1.40%), BlackRock Inc. (1.18%), ProVise Management Group LLC (0.93%), Cowen Prime Services LLC (0.92%) and EAM Investors LLC (0.90%). View Institutional Ownership Trends for Bovie Medical.
Which institutional investors are selling Bovie Medical stock?
Which institutional investors are buying Bovie Medical stock?
BVX stock was purchased by a variety of institutional investors in the last quarter, including EAM Investors LLC, BlackRock Inc., Renaissance Technologies LLC, EAM Global Investors LLC, Wells Fargo & Company MN, Columbia Pacific Advisors LLC, Perkins Capital Management Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for Bovie Medical.
How do I buy shares of Bovie Medical?
Shares of BVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bovie Medical's stock price today?
One share of BVX stock can currently be purchased for approximately $5.97.
What is Bovie Medical's official website?
How can I contact Bovie Medical?
Bovie Medical's mailing address is 4 Manhattanville Rd Ste 106, PURCHASE, NY 10577-2119, United States. The medical device company can be reached via phone at +1-727-3842323.
MarketBeat Community Rating for Bovie Medical (NYSEAMERICAN BVX)
MarketBeat's community ratings are surveys of what our community members think about Bovie Medical and other stocks. Vote "Outperform" if you believe BVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
